This study bridges a key gap in HDAC‐targeted therapy by demonstrating that precision HDAC1 inhibition can simultaneously target cancer cells and overcome immune evasion, offering a transformative paradigm for small‐molecule cancer immunotherapy. The gene discussed is HDAC1; the disease is cancer.